A human factor VIIa concentrate and its effects in the hemophilic A dog.
Properties of a new concentrate of FVII/FVIIa, obtained by adsorption onto an inorganic adsorbent followed by a chromatographic step onto Q-Sepharose using a by-product of routine fractionation as starting material, are described. This fraction contains only small amounts of the other components of the prothrombin complex but it is enriched in Proteins C and S. This preparation is essentially free of FVIIICag. It has been submitted to animal experiments including those carried out on normal and hemophilic A dogs. A normalization of the buccal bleeding time was seen after injection of a minimal dose of 4 uFVIIa/kg. No adverse reaction was observed at any dose employed. This concentrate might thus be indicated for the treatment of Haemophilia A patients with inhibitors. Its viral inactivation has been achieved.
Chabbat
J
J
Centre National de Transfusion Sanguine, Les Ulis, France.
Hampikian-Lenin
S
S
Toully
V
V
Gaillandre
A
A
Péjaudier
L
L
Steinbuch
M
M
D000818:Animals; D001760:Bleeding Time; D001794:Blood Pressure / Q000187:drug effects; D001798:Blood Proteins / Q000032:analysis; D004285:Dogs; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006467:Hemophilia A / Q000097:blood / Q000628:therapy*; D006801:Humans; D011817:Rabbits
D001798:Blood Proteins; D005167:Factor VII; D015942:Factor VIIa